IL18 was mapped to 11q22.2-22.3 in 1998. Owing to interleukin (IL)-18's important and novel role in immunomodulation, the gene itself has been subject to scrutiny, with the aim of discovering variants that may impact on disease susceptibility and/or progression. Despite being sequenced numerous times in different populations, no non-synonymous variants have been found. However, a number of polymorphisms within the proximal promoter have been verified that may interfere with transcriptionfactor-binding sites. Much of the subsequent association analyses have centred on these variants, but have yielded no consistent results, despite numerous different study populations being genotyped. IL18 has recently been resequenced in its entirety, enabling the tagging-single-nucleotide polymorphism (tSNP) methodology to be adopted. This approach has yielded interesting results, with genetic variation being shown to affect protein levels, and risk. This review aims to compile and reflect on the association data of interest published to date, with a focus on the diseases related to aberrant inflammatory control. Genes and Immunity (2007) 8, 91-99.
Introduction
Despite advances in lifestyle and medical management, cardiovascular disease remains the leading cause of death in the developed world. 1 Chronic inflammation is the hallmark of atherosclerosis; 2 numerous histopathological and clinical investigations show immunoactivation as a cause of acute coronary syndromes, 3 while sero-epidemiological studies demonstrate that elevated inflammatory markers correlate with severity, and future risk of disease. Many gene-targeted transgenic mice models have provided mechanistic evidence in support of these studies and hypotheses. 4 Interleukins (IL) are considered to be key players in the chronic vascular inflammatory response that is typical of atherosclerosis, as well as other immunorelated conditions. The expression of proinflammatory ILs and their receptors has been demonstrated within atheromatous plaques, and their levels are often positively correlated with arterial disease and its sequelae. 5 IL-18 was identified as an interferon (IFN)g-inducing factor in mice preconditioned with Propionibacterium acnes infection. 6 It was subsequently cloned and identified as a single peptide chain with a molecular weight of around 18 000. 7 Expression of the protein in Escherichia coli showed the recombinant protein induced IFNg production in peripheral blood mononuclear cells (PBMC) and enhanced natural killer (NK) cell cytotoxicity. 8 This review aims to give an overview of the current state of IL-18 genetic-epidemiology research, specifically that relevant to diseases of immune activation.
IL18 -structure and regulation
The human IL18 gene is located on 11q23. 1 and contains six exons over 20.8 kb (see Figure 1 ). The structure of the human IL18 promoter suggests that PU.1 might be a critical regulator of its activity. However, studies using the promoters of myeloid-specific genes have shown that PU.1 acts only as a weak transactivator, and that it requires cooperation with other transcription factors to promote transcription. 9 An investigation into sodium butyrate (a bacterial fermentation product)-induced IL18 expression demonstrated that the consensus PU.1-binding site was active in vitro and that overexpression of PU.1 led to activation of IL18 through this site. However, mutation analysis showed that a GC-rich region within the proximal promoter, and not the PU.1 site, was involved in in vivo sodium butyrate-induced activation. Furthermore, DNA pull-down experiments and changes in spacing between the two elements suggested that formation of a protein complex, involving both ciselements and their respective proteins, are crucial for IL18 expression. 10 
Method of action
The IL-18 receptor complex (see Figure 2 ) is a heterodimer of IL-18Ra, responsible for extracellular IL-18 binding, and IL-18Rb, responsible for signal transduction. 11, 12 Initially, it was proposed that IL-18Rb did not bind IL-18 directly, however a site-specific antagonist that prevented binding of IL-18 to IL-18Ra but not IL-18Ra:IL-18Rb, was still able to neutralize signalling through IL-18Rb; suggestive of a degree of interaction between IL-18 and IL-18Rb. 13 On binding of IL-18 to IL-18Ra, IL-18Rb is recruited and induces signalling pathways common to other IL-1R family members such as myeloid differentiation 88 (MyD88), IL-1R-associated kinase (IRAK), tumour necrosis factor receptor-associated factor 6 (TRAF6), nuclear factor kB (NF-kB), and other downstream effectors. [14] [15] [16] [17] [18] [19] IL-18 also has a soluble decoy receptor/inhibitor -IL-18-binding protein (IL-18BP). IL-18BP binds to IL-18 preventing it from associating with IL-18R and therefore inhibiting IL-18-induced IFN-g production. 20 ,21 IL-18BP can occur in six isoforms resulting from mRNA splicing, some with known biological functions, others whose function is unclear. 22 Variation within IL18 IL18 has been resequenced by the innate immunity PGA (IIPGA) collaboration (http://innateimmunity.net) and found to contain 91 polymorphic loci within a region totalling 23 kb, including the proximal promoter and 500 bp downstream of the gene. The populations genotyped were of Caucasian and African-American descent. As might be expected, the genetic diversity and heterogeneity of the African-American population was far greater than the Caucasian, resulting in weaker genewide linkage disequilibrium (LD), and a greater number of haplotypes.
Despite IL18's exons and intron-exon boundaries being resequenced on numerous occasions in different populations, no non-synonymous single-nucleotide polymorphisms (SNPs) have been found. Furthermore, no SNPs that may interfere with mRNA splicing have been discovered. However, there is variation within the 5 0 untranslated region (UTR) and 3 0 UTR, which may cause differences in translation rate and mRNA stability, as well as variation within the proximal promoter that may cause alterations in transcription rate. Therefore, in agreement with the data outlined in section IL18 -structure and regulation, it appears that inter-individual variation in IL-18 levels could be due, in part, to genetic variation within IL18.
Does variation in IL18 cause differences in protein production?
Little work has been carried out looking at the direct relationship between IL18 variation and plasma IL-18 levels. Initially, investigators concentrated largely on the IL18 A þ 105C polymorphism, a synonymous SNP within exon 4. Despite various associations showing that it may be important in asthma (see section Asthma), the SNP was not shown to be associated with differences in plasma IL-18 levels. 23 However, studies using monocytes isolated from healthy volunteers show A þ 105C may have an effect on IL18 transcription in vitro. Unstimulated monocytes with þ 105 AA genotype showed significantly higher IL-18 production, than those with þ 105 AC genotype. A trend that remained but lost significance upon stimulation. 24 Direct functional analyses using a 909 bp promoter fragment encompassing three SNPs (G-137C, T þ 113G, and C þ 127T), in front of the firefly luciferase gene showed that genetic variation within the IL18 promoter altered transcriptional activity. The wild-type construct yielded a relative luciferase activity (RLA) double that of the mutant fragment, despite no association being observed with the same variants in study populations. 25 Similar studies using a promoter fragment polymorphic at five sites (G-656T, C-607A, G-137C, T þ 113G, and C þ 127T) again showed significant differences in RLA between alleles, however only upon stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin for 48 h. No significant association with risk of multiple Figure 1 Overview of known IL18 variation before IIPGA resequencing. À656 -rs1946519; À607 -rs1946518; À137 -rs187238; þ 113 -rs360718; þ 127 -rs360717; À133 -rs360721; À132 -rs4988359; þ 105 -rs549908. 
IL-18 genetic variation and disease
SR Thompson and SE Humphries sclerosis (MS) was observed in case:control studies using the same alleles. 26 The most thorough investigation into the link between IL18 variation and IL-18 levels was carried out in the AtheroGene prospective cohort. Five IL18 SNPs were chosen in a near-tagging SNP (tSNP) manner and genotyped throughout the cohort. In single SNP analysis, two SNPs were significantly associated with circulating IL-18 levels. Using a haplotypic approach they also found a significant global association between IL18 haplotypes and age-and sex-adjusted IL-18 levels (P ¼ 0.002), with one haplotype showing 9% lower levels in comparison to the most common haplotype. However in total, haplotypes explained only 1.8% of the variability of IL-18 levels.
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IL18 variation and disease
Owing to accruing evidence suggesting that serum levels of IL-18 may impact on individual susceptibility to disease, and that IL18 variation may influence IL-18 production, a number of investigators have looked for associations between IL18 single SNPs, or haplotypes, and disease (see Table 1 ).
Atherosclerosis
Phenotypic evidence. Within the AtheroGene cohort, serum IL-18 level was identified as a strong predictor of death from cardiovascular causes in patients with coronary artery disease regardless of their clinical status at admission. This relationship was independent of other risk factors and was unaffected by other commonly used markers of inflammation such as high sensitivity (hs)-C reactive protein (CRP), fibrinogen, or IL-6. 28 Blankenberg et al. also demonstrated a similar relationship in healthy, middle-aged European men, showing baseline IL-18 concentrations were significantly higher in patients who experienced a coronary event during their followup than those who did not (225.1 vs 203.0 pg/ml; P ¼ 0.005). Again this relationship was unaffected after adjustment for other risk factors, including inflammatory markers. 29 Carotid intima-media thickness (IMT) is a commonly used clinical marker that reflects systemic atherosclerotic burden. 30 Using a study of 366 patients without histories of cardiovascular disease, IMT measures correlated positively with serum IL-18 concentrations (r ¼ 0.36, Po0.001). Again, an association that remained significant despite adjustment for traditional risk factors. 31 Levels of serum IL-18 have also been shown to correlate directly with the severity of myocardial damage and dysfunction. In 24 patients with acute myocardial infarction (MI), plasma IL-18 concentrations were found to be significantly higher than those of 12 age-and sex-matched controls. Furthermore, the maximal rise of IL-18 correlated with serum activities of creatine kinase-MB (CK-MB), aspartate transaminase (AST), and lactate dehydrogenase (LDH), suggesting that IL-18 levels correlated with severity of myocardial damage. 32 Genetic evidence. A good deal of evidence exists suggesting that the IL-18 protein may play a role in atherosclerosis progression and stability, but to date there is little evidence suggesting that the IL18 gene itself Abbreviations: CI, confidence interval; NS, not significant; OR, odds ratio; SNP, single-nucleotide polymorphism. 27 used the AtheroGene study to show variation in IL18 could influence protein production. Using those same haplotypes, they also showed that IL18 haplotypes were associated with cardiovascular mortality during follow-up.
IL-18 genetic variation and disease
No single SNP alone was associated with cardiovascular mortality, however utilizing a haplotype-based approach, haplotypes were significantly globally associated with the risk of future cardiovascular mortality (P ¼ 0.045). Excluding deaths after 4 years and adjustment for cardiovascular risk factors strengthened the association (P ¼ 0.006). Using the most common haplotype as the reference, the same haplotype that was associated with lower IL-18 levels was also associated with a decreased cardiovascular mortality risk. Only after adjustment for IL-18 levels was this association attenuated, 27 supporting the view that the genotypeassociated risk was acting through its effect on IL-18 levels.
Type I diabetes IL-18 is a strong candidate for type I diabetes as it has been shown to have a central role in autoimmunity. [33] [34] [35] [36] [37] The influence of IL18 genetic variation on disease risk has been investigated by a number of groups with differing results.
Kretowski et al.
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investigated the frequencies of known IL18 promoter polymorphisms in diabetic patients. IL18 G-137C and C-607A are two commonly studied variants and have been shown to have an effect on IL18 transcription in vitro. 26 Using 201 type I diabetic patients from the Bialystok region of Poland (96 women and 105 men, aged 23.2712.6 years), they showed a significant frequency difference between type I diabetic and healthy control subjects. Overall, the difference reflected an increase in the À137 GC genotype and a decrease in the À137 GG genotype in the type I diabetic group compared to controls, and thus an overall increase in the C allele was seen in the diabetic group. There was no significant difference in À607 allele frequencies between the disease and the control group, however the À607 AA genotype was only seen in the control subjects (at a frequency of 5.7%). Furthermore, there were significant differences in the À607/À137 haplotype frequencies between the two groups, suggesting there was an interaction of the two polymorphisms in conferring susceptibility to type I diabetes. 38 Ide et al. 39 tested the same two promoter polymorphisms in a Japanese type I diabetic case-control study group (116 patients and 114 normal controls). They showed that À607 allele frequencies differed significantly between case and controls (P ¼ 0.023); the À607 CA genotype was present at a significantly higher proportion of case compared with control subjects (69% in case vs 57.9% in control), whereas the proportion of case subjects with the AA genotype was decreased (12.1% in case vs 26.3% in controls). While there was no significant difference in À137 allele frequencies, there was again minor differences in haplotype frequencies, with a greater number of type I diabetics carrying the À607C/ À137G haplotype than control subjects.
However, Kretowski et al. provided no Hardy-Weinberg equilibrium (HWE) information, and in subsequent analysis the allele frequencies did not agree with a population in HWE (À607, P ¼ 0.0002; À137, P ¼ 0.002). 40 Many study populations are selected for some traitwhether it be health (controls), or disease (cases), or other such attributes. When a genotype departs from HWE but is seen to be associated with a trait, we must interpret the results very cautiously; the standard statistical methods used often have increased false-positive rates when using 'out of HWE' data. As it is difficult to eliminate all the causes of HWE deviation within groupshypernormal control subjects, differing ethnicities, systematic genotyping errors, selection, nonrandom mating, etc. -it is our belief that such data must be interpreted cautiously, or an appropriate statistical test be used. [41] [42] [43] Furthermore, both polymorphisms deviated from HWE due to an excess in heterozygotes, a characteristic that may significantly interfere with haplotype inference accuracy. 44 Some loci, by chance, will deviate from HWE naturally; however, in a large Caucasian sample consisting of 12 208 individuals (case-controls) and 2703 families genotypes at both loci, in both case groups and control groups, were in agreement with HWE. Furthermore, there were no differences in frequency, single SNP or haplotype, between the case and control subjects, using both a candidate SNP (À607 and À137) approach and a tSNP approach. 40 This evidence strongly suggests that a bias inherent in Kretowski et al.'s study design is responsible for the lack of HWE, therefore their results must be interpreted with caution. In the case of Kretowski et al., the authors provide little data on the ethnicity of his control subjects, or their genotyping methods, and so we believe that, in this instance, the Szeszko et al. paper provides the best analysis of the data.
A study based on both a case-control and family-trio approach provided further evidence that neither À607 or À137 is strongly associated with type I diabetes. 45 Furthermore, data presented by Mojtahedi et al. 46 in 112 patients with type I diabetes and 194 non-diabetic controls showed no significant difference in À137 or À607 allele frequencies between the two groups. However, division of the data by age of onset did reveal a significant difference in distributions of the À137 genotypes between patients with older age of onset (415 years) and control subjects, with the À137C allele seen at greater frequency in the subgroup of patients than in control subjects.
Although the studies detailed above have investigated the same polymorphisms in the same disease, they are from varying ethnicities ruling out the possibility of a meta-analysis. In conclusion, early promising evidence appeared to hint at a role for IL18 promoter variation in type I diabetes susceptibility. However, upon further inspection and testing in larger studies, it appears that IL18 variation has no major influence on susceptibility to developing type I diabetes.
Other diseases Multiple sclerosis. Because multiple sclerosis is a supposedly T-cell-mediated autoimmune disease of the central nervous system, cytokines and other molecules involved in the regulation of apoptosis are thought to be of importance in MS pathogenesis. Indeed, higher IL-18 levels have been reported in patients with chronic progression and relapsing patients in remission. [47] [48] [49] [50] Reasoning that IL-18 could be causal in MS and that genetic variants influencing IL-18 transcription could IL-18 genetic variation and disease SR Thompson and SE Humphries influence disease risk, Giedraitas et al., having discovered the promoter variants described above, investigated their effect on MS risk. Both À607 C4A and À137 G4C were genotyped in 207 patients with MS and 139 ethnically matched healthy controls, and no significant differences were found in polymorphism frequency. 26 However, by genotyping just two SNPs, little of the total genetic variation is assessed. Therefore, although from this study there appears little evidence to implicate IL18 variation in multiple sclerosis, more thorough analyses may allow an association to be identified.
Rheumatoid arthritis and juvenile idiopathic arthritis. Rheumatoid arthritis (RA) is a common inflammatory joint disease associated with progressive joint destruction and functional decline. Both genetic and environmental factors are considered to contribute to the incidence and severity of RA worldwide, and IL-18 is expressed in RA synovium with an excess of IL-18 bioactivity over its endogenous antagonists. 51 Similarly, juvenile idiopathic arthritis (JIA) is a chronic arthritis of childhood with numerous clinically distinct presentations with differing pathogenesis. 52 Maeno et al. 53 reported that serum levels of IL-18 were significantly higher in systemic JIA patients than those in other JIA subgroups and other childhood inflammatory disorders.
Sivalingam et al. 54 genotyped both À607 and À137 in 106 RA patients and 273 unrelated healthy controls of Chinese, Indian and Malay ethnicity. No significant difference in allele frequency was observed between cases and controls, however the À607 AA genotype was significantly more common in the control group than in the cases (P ¼ 0.002). In an attempt to confirm or refute these findings, both À607 and À137 were genotyped in two independent Caucasian cohorts from Germany and United Kingdom -in total, 327 confirmed RA cases and 283 healthy unrelated controls. However, owing to departures from HWE, more conservative statistical analysis was needed, meaning that few results of significance were observed, and there was no result consistent across both cohorts. 55 In a study of 362 unrelated RA patients and 339 healthy controls recruited from two Spanish hospitals, no statistically significant differences were observed for À607 and À137 allele, genotype, or haplotype frequencies. 56 Finally, a Polish case:control study 57 showed that neither the À137 or À607 polymorphisms were significant factors influencing RA course or severity.
Less data exist to characterize IL18's role in JIA. Defining JIA as arthritis of at least 6 weeks duration of unknown cause occurring in children less than 16 years old who were antinuclear antibodies (ANA)-positive, an initial study showed no difference in polymorphism (À607, À137, þ 113, þ 127, À133) frequencies between the JIA subjects (n ¼ 86) and the control group (n ¼ 270). However, there is no detail provided on the specific JIA subgroups investigated. 58 In a smaller study consisting of 33 Japanese patients with JIA, a haplotype of 13 SNPs was seen at a significantly higher frequency than the control group when all subgroups of JIA patients were pooled together. 59 Significant associations were also seen in the subgroups of oligoarthritic and polyarthritic JIA, but not systemic JIA. However, systemic JIA patients homozygous for the haplotype had significantly higher serum IL-18 levels than others, suggesting that IL18 variation may also play a role in systemic JIA pathogenesis.
Therefore, as with type I diabetes, there is little consistent data to implicate IL18 promoter variation in RA and JIA pathogenesis. However, much of the work has concentrated on few polymorphisms in different ethnicities, or differing disease subgroups. By doing this, each study has little power and cannot be related to others; with the available online resources, a more complete investigation is now feasible and may well produce results with greater consequence and confidence.
Asthma. IL-18 concentrations in the sera from patients with asthma and atopic dermatitis are consistently elevated compared to controls. [60] [61] [62] [63] [64] In 221 asthmatic children aged 1-18 years of age, 276 asthmatic adults 18-78 years old and 85 adult controls, IL-18 levels were again elevated in asthmatic patients compared to controls. Specifically, the average serum IL-18 concentration in patients with asthma was 221 pg/ml, significantly higher than that of controls (128 pg/ml, Po0.0001). In order to determine whether this difference was due to genetic factors, the þ 105 A4C SNP was genotyped throughout the cohort. 23 The frequency of the A allele for patients with asthma was 0.89, significantly higher than that for controls (0.82) (Po0.01). The odds ratio (OR) of carrying one of the two A alleles vs none was calculated as 1.83 (1.37-2.26). In order to exclude that this significance is due to the chance of population admixture, allele frequencies of b2-ADR-16-Arg/Gly were measured. The frequency of Arg allele for patients with asthma was similar to that from controls. 23 In an attempt to repeat the above findings, Shin et al. 65 genotyped a number of polymorphisms in a Korean asthma cohort. Although no polymorphism showed a significant association with the risk of asthma development, analyses of associations with specific serum immunoglobulin E (IgE) levels to Dermatophagoides farinae and D. pteronyssinus (common aeroallergens) revealed significant associations with þ 105. Both associations showed dose-dependent patterns with carriers of the common allele ( þ 105A) having higher IgE levels than those carrying the rare allele, 65 data in agreement with the earlier findings.
Heinzmann et al. 58 genotyped both À607 and À137 (among others) in a cohort of 228 asthmatic children, but no polymorphisms differed significantly in frequency between the control and case groups. Recently studies in the large multi-centre SAPALDIA cohort, 66 ,67 a population-based study of 9561 Swiss adults, investigated the relationship of À137 on asthma. The À137G allele was associated with a markedly increased risk of atopic, but not non-atopic, asthma, findings in agreement with À137's affect on transcription described by Giedraitis et al.
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Considering the available data, variation within IL18 does appear to influence asthma risk. The SAPALDIA study provides the most convincing evidence given its size, and genotyping of þ 105 in a similarly sized study may clarify its involvement.
Crohn's disease and ulcerative colitis. The aetiology of inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn's disease (CD), is currently unclear. However, it is recognized as a multifactorial IL-18 genetic variation and disease SR Thompson and SE Humphries disease with chronic inflammation, a hallmark of the various different conditions. As IL-18 is expressed by intestinal epithelial cells under normal physiological conditions, it has been suggested that it may play a role in mucosal immunity. 68 By resequencing of the entire IL18 coding region, Tamura et al. found the same þ 105 variant to be the only SNP within the exonic sequence. The SNP was genotyped in 134 patients with CD, 110 patients with UC and 110 unrelated healthy controls. They found a significant difference in allele frequency between CD patients and healthy controls (P ¼ 0.006), associated with an OR (95% CI) of 2.19 (1.24-3.87). However, there was no association between þ 105 and UC. 69 Glas et al. 70 determined genotypes of À607, À137 and þ 105 in 210 patients with CD, 140 patients with UC and 265 healthy controls, with no significant differences in genotype or haplotype frequencies observed between the groups.
Acute graft-versus-host disease. Acute graft-versus-host disease (aGVHD) remains a significant cause of mortality and morbidity after allogeneic bone marrow transplantation (BMT). The pathogenesis of aGVHD involves the deregulation of inflammatory cytokines and donor T-cell responses. 71 Studies have shown that serum levels of IL-18 were elevated in patients with aGVHD following allogeneic BMT, and that they correlated well with the severity of the disease. [72] [73] [74] However, using murine BMT models, it has been shown that blockage of IL-18 by monoclonal antibodies after allogeneic BMT increases aGVHD-related mortality. Similarly, administration of IL-18 significantly improved survival and caused less clinical features of aGVHD. 75 Reddy et al. 76 also showed that pretreatment of donors with IL-18 also significantly improved survival, and aGVHD pathological features post-transplantation. These findings contradict the seroepidemiological data and seem to imply a protective effect against aGVHD for IL-18.
Genotyping of À137 G4C, À607 C4A and À656 G4T in 157 consecutive donor/patient pairs, within which 72 patients developed grades II-IV aGVHD, there was no association between the incidence and severity of aGVHD and donor/patient haplotypes. However, when analysing donor/patient haplotype and survival, the GCG haplotype (frequency 57%) was associated with significantly decreased transplant-associated mortality at 100 days and 1-year. 77 The Kaplan-Meier estimate (95% confidence interval (CI)) of 1-year survival for the entire cohort was 52% (44-60%), with survival at 1 year being 57% (49-66%) for patients with the GCG haplotype vs 32% (16-49%) for the remaining haplotypes. Both survival and transplantrelated mortality were not affected by donor haplotypes. Multiple regression analysis showed an effect of the GCG haplotype on mortality independent of other common mortality-associated factors, and that the presence of the GCG haplotype was associated with a twofold increased probability of survival. 77 
Conclusion
The volume of research investigating the association of IL18 variation and disease is limited and diverse, meaning there are few direct comparisons to be made. Although IL18 genetic variation has been implicated in inter-individual IL-18 serum level variation, this analysis has been carried out in one large study alone and requires further corroboration.
The available genetic data is largely contradictory, reflecting the small groups used, the many different diseases and ethnic groups investigated. Also, LD is relatively strong across IL18, meaning the effect of other markers linked to those investigated may be behind the effect. Given that LD differs between ethnic groups, this phenomenon may be behind the disparities observed, and could be resolved by investigations using African populations where LD is weaker.
As genotyping technology progresses, knowledge of our genome's structure expands, and multi-SNP studies becomes more feasible, our understanding of IL18's role in disease will improve.
